FindTrial
Sign In

Early detection of arterial hardening using PeriScope as a predicative risk factor for future heart diseases following doxorubicin as chemotherapy for cancer treatment

Arterial Stiffness as an Independent Predictor of Doxarubicin Induced Cadiomyopahty in Cancer Patients through periscope

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041879
Enrollment
108
Registered
2022-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Sponsors

Dr Mehdi Ali Mirza
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients receiving doxorubicin chemotherapy cumulative dose less than 360 mg/m2 for the first time. 2. Patients of either gender aged between 18 to 70 years. 3. Patient able to comply with the study related procedures.

Exclusion criteria

Exclusion criteria: 1. Patients with pre-existing cardiac abnormalities 2. Patients with any limb deformities.

Design outcomes

Primary

MeasureTime frame
Periscope readings for determining arterial stiffness will be continued at 10 time points in patients receiving doxorubicin based chemotherapy regimenTimepoint: Day 0,3,20,22,41,43,62,64,90,180—

Secondary

MeasureTime frame
Incidence of Arterial stiffness, Incidence of cardiomayopathyTimepoint: Day 0 and 180;Time to arterial stiffness from base line, Time to cardiomyopathy from baseline, Time to cardiomayopathy from arterial stiffnessTimepoint: Day 0,3,20,22,41,43,62,64,90,180—

Countries

India

Contacts

Public ContactDr Karunasree P

ESIC Medical College and Hospital

g.vishesh@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026